Atara Biotherape Stock Price, News & Analysis

Atara Biotherapeutics announced significant results from its Phase 3 ALLELE study of tabelecleucel (tab-cel), showing a 50% objective response rate (ORR) in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD). The one-year survival rate for responders reached 89.2%, indicating a substantial survival advantage. Safety data remained consistent, with no new concerns. The findings will be presented at the American Society of Hematology Annual Meeting in December 2021, highlighting tab-cel’s transformative potential in treating EBV-driven diseases.

Atara Biotherapeutics (Nasdaq: ATRA) reported Q3 2021 results, highlighting significant progress in its pipeline, including pivotal Phase 3 data for tab-cel®, accepted for oral presentation at the American Society of Hematology meeting. The company plans to submit its EU Marketing Authorization Application imminently, with an FDA Biologics License Application expected in Q2 2022. Notable advancements also include promising data for ATA188 in treating progressive MS and ongoing development of CAR T therapies. Financially, Atara reported an $84.7 million net loss for Q3, reflecting increased R&D and operational expenses.

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) will release its third quarter 2021 financial results on Thursday, November 4, 2021, before the market opens. Following this, a live conference call will take place at 8:30 a.m. EDT for analysts and investors to discuss the results and provide corporate updates. Atara is recognized for its innovative T-cell immunotherapy platform focused on treating cancers and autoimmune diseases, with lead programs in advanced clinical development, particularly targeting Epstein-Barr virus-related ailments.

Atara Biotherapeutics (ATRA) announced promising data from its Phase 1 clinical study of ATA188, a T-cell immunotherapy targeting EBV-infected cells in progressive multiple sclerosis (MS) patients. The interim analysis highlights significant sustained disability improvement in 7 of 8 patients, alongside increased magnetization transfer ratio (MTR) readings suggestive of remyelination. The ongoing open-label extension study tracked these patients for up to 39 months, with no new adverse effects noted. Atara plans to conduct an interim analysis from its randomized Phase 2 EMBOLD study in H1 2022.

Atara Biotherapeutics and Pierre Fabre have signed an exclusive commercialization agreement for Tab-cel® in Europe, the Middle East, Africa, and select emerging markets, targeting EBV-positive cancers. Atara will receive an upfront payment of USD 45 million, with potential milestone payments of up to USD 320 million, plus tiered royalties from net sales. Atara retains commercialization rights in the US and other major markets. The EU Marketing Authorization Application for Tab-cel® is on track for submission in November 2021.

Atara Biotherapeutics, Inc. announced the grant of 104,386 restricted stock units and stock options to newly hired employees, approved by its Compensation Committee under the 2018 Inducement Plan. The restricted stock units vest over four years, while the stock options provide a ten-year term with an exercise price of $17.50 per share, set to the closing price on the grant date of October 1, 2021. This move is compliant with Nasdaq Listing Rule 5635(c)(4), highlighting Atara's commitment to building a skilled workforce.

Atara Biotherapeutics announced new data on ATA188 for progressive multiple sclerosis (MS), highlighting a two-year open-label extension (OLE) study. Significant findings include improved magnetization transfer ratio (MTR) indicative of possible remyelination and sustained disability improvement in patients over 33 months. Of 24 patients evaluated, 18 continued in the OLE, with 9 meeting sustained disability improvement criteria. The data presentation is scheduled for October 13, 2021, at the ECTRIMS Congress, showcasing Atara's commitment to developing innovative T-cell therapies for MS.

Atara Biotherapeutics (NASDAQ: ATRA) announced that the European Medicines Agency's CHMP granted accelerated assessment for its lead product candidate, tabelecleucel (tab-cel), aimed at treating Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD). Currently, there are no approved therapies for this life-threatening condition. The Marketing Authorization Application (MAA) is expected to be submitted in November 2021, with a potential approval decision anticipated in the second half of 2022.

Atara Biotherapeutics (Nasdaq: ATRA) announced the grant of 74,055 restricted stock units and stock options for 59,869 shares to newly hired employees. These awards, part of Atara's 2018 Inducement Plan, were approved by the Compensation Committee. The RSUs vest over four years, while the stock options have a ten-year term with an exercise price of $15.69 per share. This initiative aims to attract and retain talent in the competitive biotherapeutics market, adhering to Nasdaq rules.